Catch up with our insights on the big issues in pharma.
Our thought leadership library brings you our latest data-driven reports, infographics and articles that tackle the big issues, interesting niches and everything in between.
Q4 2026 brings 633 catalysts, including 100 approval decisions and 112 top-line readouts. This report profiles five that face FDA decisions or Phase III data, with the likelihood of approval and the Biomedtracker...
Cost per new drug has more than doubled, and development timelines are heading toward 10 years. How can competitive intelligence teams take industry benchmarks and turn them into competitive signals that will s...
Over 60 potential launches across 15 therapy areas. This report profiles five 2027 candidates with the scale and science to lead their markets, and the commercial questions that will decide how far they...
A forecast model that only its creator can navigate is a liability. Bad model design shows up as stakeholders who distrust the outputs, scenarios that aren’t run, and forecasting teams that spend time...
The Latest Best Estimate keeps a commercial plan honest through the year. From how to define the right LBE cadence, to making risk and opportunities explicit in your forecasting, this article sets out...
